Posted by Michael Wonder on 09 Nov 2024
Caris Life Sciences receives FDA approval for MI Cancer Seek as a companion diagnostic test
6 November 2024 - MI Cancer Seek is the first and only simultaneous whole exome and whole transcriptome-based assay with companion. diagnostic indications for adults and paediatric patients.
Caris Life Sciences today announced the US FDA has approved MI Cancer Seek for use as a companion diagnostic to identify cancer patients who may benefit from treatment with targeted therapies.
